Skip to main content

Table 3 Comparison of BAE and non-BAE subjects with hemoptysis

From: Hemoptysis requiring bronchial artery embolization in patients with nontuberculous mycobacterial lung disease

 

Medical (n = 45)

BAE (n = 33)

P-value

Male sex

12 (26.7)

15 (45.5)

0.098

Age, years, at diagnosis

59.5 ± 11.7

60.0 ± 12.1

0.855

BMI, kg/m2

20.5 ± 2.6

19.8 ± 2.9

0.274

Diabetes mellitus

2 (4.4)

4 (12.1)

0.392

Hypertension

8 (17.8)

7 (21.2)

0.704

Performed bronchoscopy

28 (62.2)

24 (72.7)

0.466

Type of chest CT

 Nodular bronchiectatic

38 (84.4)

28 (84.8)

0.961

 Fibrocavitary

7 (15.6)

5 (15.2)

 

> 3 lobe distribution of chest CT

8 (17.8)

12 (36.4)

0.073

Antiplatelet/anticoagulation therapy

5 (11.1)

5 (15.2)

0.735

Liver disease

4 (8.9)

5 (15.2)

0.726

History of pulmonary tuberculosis

15 (33.3)

16 (48.5)

0.242

Charlson Comorbidity Index score

1.04 ± 1.1

1.6 ± 2.0

0.119

2 NTM pathogens identified

4 (8.9)

1 (3.0)

0.389

Complication after BAE

 

0

 

Repeat BAE due to rebleeding

 

8 (24.2)

 

Duration between first BAE and rebleedinga

 

10 (7.5–53.5)a

 

Number of BAE trials

 1

 

25 (75.8)

 

 2

5 (15.2)

 5

2 (6.1)

 8

1 (3.0)

  1. Results are presented as n (%) or mean ± standard deviation, unless otherwise indicated
  2. BAE bronchial artery embolization, BMI body mass index, CT computed tomography, NTM nontuberculous mycobacteria, M. Mycobacterium
  3. athis value is presented as median (interquartile range) because of the small number of subjects